US9944651B2 refers to piperazine-based pyrrolo[2,1-f][1,2,4]triazine derivatives for treating conditions like mastocytosis and mast cell diseases by modifying the activity of KIT. This evidence concerns the gene KIT and maculopapular cutaneous mastocytosis.